Codexis also reported revenue of $38.92 million, exceeding expectations by 16.01%. This robust earnings report highlights Codexis’ ability to outperform market predictions. These developments ...
Reports revenue of $15.2 million for the first quarter, company reiterates full-year financial guidanceThree presentations at upcoming TIDES USA ...
8d
Earnings Release: Here's Why Analysts Cut Their Codexis, Inc. (NASDAQ:CDXS) Price Target To US$6.58
A week ago, Codexis, Inc. (NASDAQ:CDXS) came out with a strong set of first-quarter numbers that could potentially lead to a re-rate of the stock. Revenues and losses per share we ...
Q1 2026 Management view Dr. Alison Moore said the company “accomplished a lot” since the prior call and plans to present “important new data on our ECO Synthesis technology” at the TIDES Conference, ...
Over the last 7 days, the United States market has risen by 2.2%, and over the past year, it has increased by 31%, with earnings forecasted to grow annually by 17%. In light of these conditions, ...
Codexis CDXS will release its quarterly earnings report on Wednesday, 2025-08-13. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Codexis to report an earnings per ...
REDWOOD CITY, Calif. (AP) — REDWOOD CITY, Calif. (AP) — Codexis Inc. (CDXS) on Thursday reported a loss of $8.7 million in its first quarter. On a per-share basis, the Redwood City, California-based ...
Codexis outlined ongoing commercial discussions supported by a "very, very healthy" sales funnel spanning large pharma, ...
Wall Street finally started paying attention to Codexis (NASDAQ: CDXS) in 2017. But as investors are now being reminded, extra attention can bring extra scrutiny. While long-term investors have ...
REDWOOD CITY, Calif., March 11, 2026 (GLOBE NEWSWIRE)-- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today ...
REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results